Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

194 result(s)

  • Paris, Saint-Cloud
    LE DECLIC-EPRI (IC 2019-06)
    DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI.

    EVELYNE RENAULT TESSIER

  • Childhood and adolescent cancers
    Paris
    LYNPARZA (D0816C000025)
    A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours

    ISABELLE AERTS GAJDOS

  • Bladder cancer
    Paris
    MK3475-992
    A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)

    GILLES CREHANGE

  • ENT/Head and Neck Cancers
    Paris
    MK7902-009 (LEAP-009)
    Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

    CHRISTOPHE LE TOURNEAU

  • Breast cancer
    Paris, Saint-Cloud
    MONDRIAN
    Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    MS100070-0087
    Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.

    FRANCOIS DOZ

  • Lung cancer
    Paris
    MYTX-011-01
    MYTX-011-01 : A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer · KisMET-01

    NICOLAS GIRARD

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    NIVOPOST-OP / GORTEC 2018-01
    A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

    CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC

  • Paris
    PLUME
    A phase II, monocentric, single arm trial;evaluating the efficacy and safety of;Pembrolizumab in combination with Lenvatinib;in metastatic Uveal MElanoma patients

    MANUEL RODRIGUES

  • Prostate cancer
    Paris
    PRESTO (GETUG-AFU 36)
    Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial

    GILLES CREHANGE

  • Lung cancer
    Paris, Saint-Cloud
    REAL MOOV LUNG
    Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ROMANCE (RAD05-UC-0107/1803)
    Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast

  • Prostate cancer
    Paris, Saint-Cloud
    TEMPOS (GETUG P14)
    Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy

    GILLES CREHANGE

  • Sarcomas
    Paris
    ADCT-601-102
    A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

    SARAH WATSON

  • Lung cancer
    Paris
    AK112-301-HARMONi
    A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-2
    Analysis of Circulating Tumor Markers in Blood

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    BGB-LC-201
    A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI1438-0009 (DAREON 9)
    DAREONTM-9: A Phase Ib open-label dose escalation and dose;confirmation safety study of intravenous BI 764532 in;combination with topotecan for the treatment of patients with;small cell lung cancer

    PAULINE DU RUSQUEC

  • Lung cancer
    Paris
    BRIDGE (D9106C00002)
    A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

    NICOLAS GIRARD

  • Paris
    DS 73001-003
    A PHASE 2, MULTICENTER, RANDOMIZED, OPENLABEL;STUDY OF DS-7300A, A B7-H3 ANTIBODY;DRUG CONJUGATE (ADC), IN SUBJECTS WITH;PRETREATED EXTENSIVE-STAGE SMALL CELL;LUNG CANCER (ES-SCLC).

    PAULINE DU RUSQUEC

  • Paris, Saint-Cloud
    EMBER-3 (J2J-OX-JZLC)
    EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    ENCO-BRAF (IFCT-1904)
    A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

    CLEMENCE BASSE

  • Breast cancer
    Saint-Cloud
    FAP-IT
    68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

  • Paris
    GCT1047-01
    First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    GSK213406
    A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

    FRANCOIS DOZ

  • ENT/Head and Neck Cancers
    Paris
    HPV.DCVax
    Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer.

    CHRISTOPHE LE TOURNEAU

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • Lung cancer
    Paris
    DS1062-A-U303/ TROPION-Lung07
    A Randomized Phase 3 Study of Datopotamab Deruxtecan;(Dato-DXd) and Pembrolizumab, with or Without Platinum;Chemotherapy, in Subjects with No Prior Therapy for;Advanced or Metastatic PD-L1 TPS <50% Non-squamous;Non-small Cell Lung Cancer Without Actionable Genomic;Alterations;(TROPION-Lung07)

    NICOLAS GIRARD

  • Eye tumors / Uveal melanoma
    Paris
    IDE 196-002
    IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigator·s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).

    SOPHIE PIPERNO-NEUMANN

  • Breast cancer
    Paris, Saint-Cloud
    TOPOLOGY
    A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

    FRANCOIS-CLEMENT BIDARD

<
1 ...7
>